RNLXY · Renalytix plc
$4.15
-0.34 (-7.47%)
At close · Sep 4
Going-concern doubt
— flagged Nov 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“As a result of the Company's losses and its projected cash needs, as defined in the accounting literature, substantial doubt exists about the Company's ability to continue as a going concern. While subsequent to September 30, 2024, the company has successfully raised approximately $14.9 million, net of expenses, in new equity capital and restructured the existing long-term debt recorded on the balance sheet, the Company does have a history of operating losses and it has been expensive to deliver all of the milestones to commercialize the kidneyintelX.dkd test. … As such, management has concluded that there is a going concern uncertainty. The consolidated financial statements do not include any adjustments that may result from the outcome of this going concern uncertainty.”View the 10-Q filed Nov 19, 2024
Market Cap
$2.20M
Shares
529,930
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.15
Open$4.49
Day$4.15–4.64
Since split$1.10–4.49
Avg vol 30d10K
Short int327 · 0.1% float · 1.0d
Short vol29%
Last earningsMay 15, 2024
DataDec 2025–Sep 2026
Filing10-Q · Nov 19
Raw chart and full-history price indicators begin at the captured split on Dec 16, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Dec 16, 2025.
Up next
filed Nov 19, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.35M
Trailing 12 months
Net income (TTM)
−$28.03M
Trailing 12 months
Revenue growth YoY
+13.7%
Year over year
Operating margin
-1,054.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+11.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+82%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
90%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+66%
trailing
6-month return
+32%
trailing
YTD return
+15%
this year
Relative strength
+17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.06% of float · ▼ -99.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
−33%
Y/Y
Gross margin
7%
contracting
EPS growth
+44%
Y/Y
Free cash flow
$-30.1M
Quant / Vol
risk profile
Volatility
120%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+82%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
90%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.06% of float · ▼ -99.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its range since split · 2025-12-16
Range low $1
Now $4 · 90%
Range high $4
vs 50-day avg +82%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNLXY
this stock
Renalytix plc
|
$2.20M | +14.6% | -32.7% | — | 0.1% |
|
VEEV
Veeva Systems Inc
|
$44.54B | +23.2% | +28.1% | 45.0 | 3.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$13.01B | -25.0% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.02B | +62.2% | +28.2% | 36.8 | 4.5% |
|
TEM
Tempus AI, Inc.
|
$11.66B | +9.4% | +83.4% | — | 16.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Dec 16, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNLXY | +56.0% | +66.3% | +32.3% | +57.0% | +14.6% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +55.9% | +66.7% | +17.2% | +56.6% | +1.7% |